Novo Nordisk Shares Face Mounting Challenges

The Danish pharmaceutical giant Novo Nordisk is confronting significant pressure across multiple areas of its business. A failed multi-billion dollar acquisition, disappointing quarterly earnings, and substantial price reductions for its key drug Wegovy have contributed to a sharp decline in its stock value. The central question for investors is whether the company can reverse this downward trend.

Disappointing Earnings and a Dimmer Outlook

Recent financial results have heightened investor concerns. For the third quarter of 2025, Novo Nordisk reported revenue of $11.74 billion, falling short of the $11.88 billion forecast by market analysts. In a move that further unsettled the market, company management promptly revised its full-year guidance downward. The firm now anticipates revenue growth of just 8 to 11 percent at constant exchange rates, a step back from its previous expectation of double-digit growth.

The underperformance is notably linked to the company’s flagship GLP-1 medications, Wegovy and Ozempic. Once considered reliable growth drivers, these drugs are now showing signs of weakness, with their expansion in the crucial U.S. market lagging significantly behind projections.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

A Major Acquisition Falls Through

In a separate strategic setback, Novo Nordisk was forced to withdraw from the bidding contest for the obesity specialist Metsera. The U.S. Federal Trade Commission (FTC) had signaled antitrust concerns, effectively blocking the Danish firm’s path. Rival Pfizer subsequently secured the acquisition for approximately $10 billion. This outcome represents a significant defeat for Novo Nordisk, which had viewed the deal as a strategic move to bolster its product pipeline. The company is now left to rely more heavily on its internal research and development efforts in an increasingly competitive obesity drug market.

Price War Intensifies, Squeezing Margins

Mounting competitive pressure, particularly from Eli Lilly’s successful product Mounjaro, has prompted Novo Nordisk to take aggressive pricing actions. The company has slashed the price of Wegovy by up to 37 percent in India and accelerated price reductions for self-paying customers in the United States. While framed as a market strategy, these deep discounts are widely interpreted as a sign of mounting pressure, with the ensuing margin compression occurring amidst a brutal fight for market share.

The cumulative impact of these developments is starkly reflected in the company’s stock performance. Since the start of the year, Novo Nordisk’s share price has plummeted by over 42 percent. The financial community is taking note; analysts at BMO Capital Markets have reduced their price target from $55 to $50, citing disappointment over the failed Metsera takeover and the company’s recent strategic stumbles.